Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Acumapimod (BCT-197) is an orally active inhibitor of p38α MAPK (IC50 <1 μM).
説明 | Acumapimod (BCT-197) is an orally active inhibitor of p38α MAPK (IC50 <1 μM). |
ターゲット&IC50 | p38α:<1 μM |
In vivo | Acumapimod increases survival and reduces the number of macrophages in bronchoalveolar lavage fluid (BALF) in a mouse model of infection with influenza H1N1 A/PR/8/34 when administered at a dose of 6 mg/kg[1] |
動物実験 | In vivo, female BALB/c mice were infected intranasally with 150 pfu of influenza H1N1 A/Puerto Rico/8/34 and treated with Acumapimod(BCT197) (a closely related p38 MAPK inhibitor with an IC50 value of<1?μM, currently in clinical testing), dexamethasone or oseltamivir (Tamiflu) starting 24?h post infection. Body weight, bronchoalveolar lavage cells, cytokines, total protein and lactate dehydrogenase as well as serum cytokines were measured; a subset of animals was evaluated histopathologically[1]. |
別名 | BCT-197 |
分子量 | 385.42 |
分子式 | C22H19N5O2 |
CAS No. | 836683-15-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (129.73 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Acumapimod 836683-15-9 Autophagy MAPK p38 MAPK inhibit BCT197 Inhibitor BCT-197 BCT 197 inhibitor